Company intelligence / Profile preview
Kangzhong (Beijing) Biotechnology Co., Ltd.
- Ownership
- Private
- Development stage
- Other
Overview
Kangzhong (Beijing) Biotechnology Co., Ltd. specializes in R&D, manufacturing, and distribution of vaccines, diagnostic reagents, and antibody-based drugs targeting human infectious diseases. Its leading program involves a recombinant Mycobacterium tuberculosis fusion protein ("D‑EC") for skin testing in TB diagnosis. Clinical trials include a completed Phase I study evaluating safety/tolerability and an ongoing/not-yet-recruiting Phase IIb trial assessing safety/tolerability across age groups. The company’s competitive edge lies in innovative infectious disease products aimed at prevention, detection, and treatment within China.
- Therapeutic areas
- Infectious Diseases
- Modalities
- VaccinesDiagnostic reagentsAntibody-based pharmaceuticals
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Kangzhong (Beijing) Biotechnology Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kangzhong (Beijing) Biotechnology Co., Ltd..